Filing Details

Accession Number:
0001209191-19-009116
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-11 19:10:23
Reporting Period:
2019-02-11
Accepted Time:
2019-02-11 19:10:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1604464 Atara Biotherapeutics Inc. ATRA Biological Products, (No Disgnostic Substances) (2836) 460920988
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1612095 Christopher Haqq 611 Gateway Boulevard
Suite 900
South San Francisco CA 94080
Evp, R&D & Chief Scientific Of No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-02-11 13,975 $38.55 272,718 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 17,312 Indirect See footnote
Common Stock 2,688 Indirect See footnote
Footnotes
  1. Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018.
  2. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.27 to $38.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
  4. The shares are held by The Havenside Trust, of which the Reporting Person is trustee.